Blend: BPC-157 TB-500 Peptide (20MG)

This page covers two separate papers:

• BPC 157: Matek et al. (2025), Pharmaceutics. A rat study of oral BPC 157 after surgical detachment of the quadriceps muscle.
• Thymosin β4: Philp and Kleinman (2010), Annals of the New York Academy of Sciences. A review of animal studies of thymosin β4 in eye, skin, heart, brain and sepsis models.

The studies used different species, models, routes and outcomes. Their results cannot be combined, and they do not provide evidence about the two compounds used together.

Design: Male Wistar rats (6 per group per time point) had the quadriceps surgically detached from its attachments on the femur and pelvis. They received BPC 157 by mouth, first by stomach tube and then in drinking water, or plain water. Researchers assessed them from day 1 to day 90.

Findings reported by the authors: Compared with water-treated controls, BPC 157-treated rats showed:

• Better Walking Recovery Index and Motor Function Index scores
• Elimination of the leg contracture seen in controls
• Thigh muscle diameter closer to normal
• A smaller muscle-to-bone gap on ultrasound, and findings consistent with reattachment on MRI and histology

Limitations: One rat model, small groups and male animals only. Much of the published BPC 157 research comes from the same research group.

Design: A narrative review of published animal studies of thymosin β4, a naturally occurring 43-amino-acid, actin-binding peptide.

Findings described in the review:

• In rat and mouse eye- and skin-injury models, topical Tβ4 was associated with faster wound closure. In skin wounds, it was also associated with more collagen deposition and angiogenesis.
• In mouse and pig heart models, Tβ4 was associated with better cardiac cell survival or smaller infarct size.
• In rat brain-injury, mouse autoimmune encephalomyelitis and rat endotoxin-shock models, it was associated with reduced neuron loss, inflammation or mortality.

Limitations: Each finding comes from a separate study. Most studies used full-length Tβ4, which may differ from materials sold as TB-500. One author disclosed consulting for a company developing Tβ4.

• Structure: BPC 157 is a 15-amino-acid peptide (GEPPPGKPADDAGLV) based on a partial sequence of a protein found in gastric juice. Tβ4 is a 43-amino-acid peptide found inside almost all mammalian cells.
• Proposed activity: BPC 157 studies by the Zagreb group emphasize blood-vessel and nitric oxide-related effects. Tβ4 studies emphasize actin binding, cell migration and inflammatory signaling.
• Models: The BPC 157 study used oral delivery in a rat muscle-to-bone injury model. The Tβ4 review covers topical and systemic delivery across many models and species.

• No referenced study tested BPC-157 and TB-500 together. Any claim of combined or "synergistic" effects would not be supported by these papers.
• Neither paper establishes effects, safety or dosing for either compound in people.
• Results from one injury model or species should not be generalized to others.

The BPC 157 rat study (Matek et al., 2025) and the thymosin β4 animal review (Philp & Kleinman, 2010) each describe findings for a single compound in experimental animal models. Researchers interested in either compound should review each source on its own terms. The combination of the two has not been studied in the referenced literature.

This summary is provided for research and educational purposes. Statements on this page have not been evaluated by the FDA. Research compounds offered on this site are for laboratory research use only. They are not intended for human or veterinary use, or to diagnose, treat, cure, mitigate or prevent any disease.